Bridging Academic Insights and Industrial Practices: Upstream Process Development in Mammalian Cell-Based Biopharmaceutical Production

Abstract

Biopharmaceuticals, particularly those produced using mammalian cell systems, have reshaped modern therapeutic approaches by enabling the production of complex and efficacious recombinant proteins. This study provides a comprehensive analysis of upstream process development strategies in mammalian cell-based biopharmaceutical manufacturing, with a particular emphasis on CHO cells due to their dominance in the industry. Core components such as cell line selection, culture modes, media design, feeding strategies, and bioreactor systems are critically evaluated in terms of productivity, scalability, cost-effectiveness, and regulatory adaptability. Mammalian cell culture methods are compared to highlight their respective advantages for different therapeutic protein profiles, with fed-batch processes remaining industry standard, while perfusion systems gain relevance for labile or high-value proteins. Media strategies are explored in depth, focusing on nutrient formulation, waste metabolite control, and the role of media composition in modulating post-translational modifications such as glycosylation and sialylation. Additionally, the study examines various bioreactor systems ranging from reusable stainless steel tanks to single-use and wave-type bioreactors and assesses them based on operational complexity, shear sensitivity, and scalability. Future-oriented approaches, including AI-driven bioprocess optimization, digital twin modeling, and continuous manufacturing, are briefly addressed.. By integrating academic insights with industrial needs, this study aims to guide the development of more robust, flexible, and sustainable upstream processes for mammalian cell-based biopharmaceutical production in an increasingly competitive and innovation-driven global market.